← Back to Screener
Palisade Bio, Inc. Common Stock (PALI)
Price$2.08
Value ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-25.33%
Price vs S&P 500 (4W)1.56%
VGM Score47.23
Market Capitalization$367.99M
All Metrics
Book Value / Share (Quarterly)$0.76
P/TBV (Annual)1.58x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.07
Price vs S&P 500 (YTD)-20.72%
Net Profit Margin (TTM)-936.00%
EPS (TTM)$-1.17
10-Day Avg Trading Volume2.77M
EPS Excl Extra (TTM)$-1.17
EPS (Annual)$-10.19
ROI (Annual)-190.70%
Net Profit Margin (5Y Avg)-37513.22%
Cash / Share (Quarterly)$0.79
ROA (Last FY)-132.70%
EBITD / Share (TTM)$-0.38
ROE (5Y Avg)-188.72%
Operating Margin (TTM)-1011.60%
Cash Flow / Share (Annual)$-0.07
P/B Ratio2.89x
P/B Ratio (Quarterly)2.30x
Net Income / Employee (Annual)$-1,031,300
EV / Revenue (TTM)941.44x
Net Interest Coverage (TTM)-1202.17x
ROA (TTM)-34.34%
EPS Incl Extra (Annual)$-10.19
Current Ratio (Annual)28.95x
Quick Ratio (Quarterly)23.60x
3-Month Avg Trading Volume3.72M
52-Week Price Return207.25%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1896.75
P/S Ratio (Annual)1471.96x
Asset Turnover (Annual)0.02x
52-Week High$2.85
Operating Margin (5Y Avg)-29730.27%
EPS Excl Extra (Annual)$-10.19
Tangible BV CAGR (5Y)20.01%
26-Week Price Return-9.40%
Quick Ratio (Annual)28.83x
13-Week Price Return14.59%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)23.71x
Enterprise Value$235.36M
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-79.85%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4920.00%
Cash / Share (Annual)$0.84
3-Month Return Std Dev86.06%
Net Income / Employee (TTM)$-1,725,100
ROE (Last FY)-192.71%
Net Interest Coverage (Annual)-2414.10x
EPS Basic Excl Extra (Annual)$-10.19
Receivables Turnover (TTM)0.20x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.17
Receivables Turnover (Annual)0.20x
ROI (TTM)-36.71%
P/S Ratio (TTM)1471.96x
Pretax Margin (5Y Avg)-37513.22%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2405.25
Price vs S&P 500 (52W)179.04%
Year-to-Date Return-9.79%
5-Day Price Return8.72%
EPS Normalized (Annual)$-10.19
ROA (5Y Avg)-129.62%
Net Profit Margin (Annual)-4920.00%
Month-to-Date Return6.00%
Cash Flow / Share (TTM)$-2.62
EBITD / Share (Annual)$-10.49
Operating Margin (Annual)-5228.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-187.02%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.17
P/TBV (Quarterly)3.88x
P/B Ratio (Annual)2.71x
Pretax Margin (TTM)-936.00%
Book Value / Share (Annual)$0.81
Price vs S&P 500 (13W)4.85%
Beta1.44x
Revenue / Share (TTM)$0.00
ROE (TTM)-36.79%
52-Week Low$0.53
vGradeF
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.05est. -0.04
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.23
4.21
4.21
4.21
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PALIPalisade Bio, Inc. Common Stock | F | — | B | $2.08 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Palisade Bio is a clinical-stage biopharmaceutical company developing therapeutics to protect intestinal barrier function. Its lead candidate, PALI-2108, targets inflammatory bowel disease, including ulcerative colitis and Crohn's disease, while PALI-1908 is in early-stage research. The company is positioned in the gastrointestinal immunology market.